Changeflow GovPing Pharma & Drug Safety Recombinant Protein UK114 in Stable Polymer For...
Routine Notice Added Final

Recombinant Protein UK114 in Stable Polymer Form for Solid and Systemic Tumour Treatment

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office has published patent application EP3554639A1 filed by Alberto Bartorelli Cusani for a recombinant protein UK114 in stable polymer form for use in treating or preventing malignant solid and systemic tumours. The application is classified under IPC codes A61K and A61P covering therapeutic preparations. The patent has been designated across all European Patent Convention member states.

What changed

The European Patent Office published patent application EP3554639A1 for a recombinant protein UK114 in stable polymer form. The invention relates to therapeutic use in treating or preventing malignant solid and systemic tumours. Filed by Alberto Bartorelli Cusani, the application is classified under A61K (preparations for medical purposes) and A61P (therapeutic activity). Designated states cover all EPC contracting states.

Pharmaceutical companies, biotech firms, and researchers in oncology should monitor this publication for potential freedom-to-operate considerations or licensing opportunities. The patent represents a novel therapeutic approach using recombinant protein technology for solid tumour treatment.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NOVEL RECOMBINANT PROTEIN UK 114 IN STABLE POLYMER FORM FOR USE IN THE TREATMENT OR PREVENTION OF MALIGNANT SOLID AND SYSTEMIC TUMOURS

Publication EP3554639A1 Kind: A1 Apr 08, 2026

Applicants

Bartorelli Cusani, Alberto

Inventors

Bartorelli Cusani, Alberto

IPC Classifications

A61K 38/50 20060101AFI20260227BHEP A61P 35/00 20060101ALI20260227BHEP A61K 38/16 20060101ALI20260227BHEP A61K 35/66 20150101ALI20260227BHEP A61K 39/00 20060101ALI20260227BHEP A61P 37/04 20060101ALI20260227BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Recombinant Protein UK114 Solid Tumour Treatment Stable Polymer Form

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP3554639A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254.1 Biotechnology
Activity scope
Patent application Biotechnology research Oncology therapeutics
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!